Product Development
The development of a bypassing agent in 1997 offers inhibitor patients an alternative product to help stop bleeds and joint damage.
The development of a bypassing agent in 1997 offers inhibitor patients an alternative product to help stop bleeds and joint damage.
NHF's magazine, HemAware, debuts its inaugural issue.
The Hemophilia Foundation of Greater Florida forms and joins NHF as a chapter.
In 1996, the National Hemophilia Foundation initiated an annual Gene Therapy and Novel Technologies Workshop to bring together immunologists, clinicians, and researchers in gene therapy. Over two decades later, the Gene Therapy Workshop still continues today.
Val Bias, community advocate and future NHF CEO, testifies before Congress to amend the Employee Retirement Income Security Act of 1974, hoping to increase the purchasing power of individuals and employers, to protect employees whose health benefits are provided through multiple employer welfare arrangements, and to provide increased security of health care benefits.
Pharmceutical companies settle with hemophiliacs who contracted HIV/AIDs through blood products.
MASAC issues recommendations for prophylaxis treatment for individuals with r factor VIII or r factor IX.
The World Health Organization and the World Federation of Hemophilia recommend prophylaxis as the treatment of choice in children with hemophilia, based on evidence-driven studies.
Dr. Jeanne Lusher becomes the first female chair of MASAC.
The camp subcommittee of NHF's Nursing Executive Committee develops the first Hemophilia Camp Program Standards.